Cargando…

Novel FXa Inhibitor Identification through Integration of Ligand- and Structure-Based Approaches

Factor Xa (FXa), a vitamin K-dependent serine protease plays a pivotal role in the coagulation cascade, one of the most interesting targets for the development of new anticoagulants. In the present work, we performed a virtual screening campaign based on ligand-based shape and electrostatic similari...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lagos, Carlos F., Segovia, Gerardine F., Nuñez-Navarro, Nicolás, Faúndez, Mario A., Zacconi, Flavia C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151700/ https://www.ncbi.nlm.nih.gov/pubmed/28937618 http://dx.doi.org/10.3390/molecules22101588

Ejemplares similares

Direct Oral FXa Inhibitors Binding to Human Serum Albumin: Spectroscopic, Calorimetric, and Computational Studies
por: Mariño-Ocampo, Nory, et al.
Publicado: (2023)

Innovative Three-Step Microwave-Promoted Synthesis of N-Propargyltetrahydroquinoline and 1,2,3-Triazole Derivatives as a Potential Factor Xa (FXa) Inhibitors: Drug Design, Synthesis, and Biological Evaluation
por: Santana-Romo, Fabián, et al.
Publicado: (2020)

Green by Design: Convergent Synthesis, Computational Analyses, and Activity Evaluation of New FXa Inhibitors Bearing Peptide Triazole Linking Units
por: Rodríguez, Diego F., et al.
Publicado: (2021)

Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors
por: Huang, Changjiang, et al.
Publicado: (2017)

In silico Discovery of Novel FXa Inhibitors by Pharmacophore Modeling and Molecular Docking
por: Pu, Yinglan, et al.
Publicado: (2017)

Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation
por: Wang, Wenzhi, et al.
Publicado: (2016)

Use of a Genetic Variant Related to Circulating FXa (Activated Factor X) Levels to Proxy the Effect of FXa Inhibition on Cardiovascular Outcomes
por: Gill, Dipender, et al.
Publicado: (2020)

Novel Isosteviol-Based FXa Inhibitors: Molecular Modeling, In Silico Design and Docking Simulation
por: Gackowski, Marcin, et al.
Publicado: (2023)

Thromboprophylaxis in COVID-19: Anti-FXa—the Missing Factor?
por: Dutt, Tina, et al.
Publicado: (2020)

Edoxaban Exerts Antioxidant Effects Through FXa Inhibition and Direct Radical-Scavenging Activity
por: Narita, Yuki, et al.
Publicado: (2019)

Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
por: Rappaport, Stephen H., et al.
Publicado: (2020)

Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice
por: Pham, Phuong Tran, et al.
Publicado: (2019)

Quantitative Structure–Activity Relationship Analysis of Isosteviol-Related Compounds as Activated Coagulation Factor X (FXa) Inhibitors
por: Gackowski, Marcin, et al.
Publicado: (2022)

Characteristics of FXa-storing platelets in hemophilia B mice and the influence of alcohol on the platelets
por: Han, Wenwen, et al.
Publicado: (2023)

A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter
por: Farkh, Carine, et al.
Publicado: (2021)

Discovery of New Phenylacetone Monooxygenase Variants for the Development of Substituted Indigoids through Biocatalysis
por: Núñez-Navarro, Nicolás, et al.
Publicado: (2022)

Activated Blood Coagulation Factor X (FXa) Contributes to the Development of Traumatic PVR Through Promoting RPE Epithelial-Mesenchymal Transition
por: Han, Han, et al.
Publicado: (2021)

Reply to Rappaport et al.: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
por: Dutt, Tina, et al.
Publicado: (2020)

Antibodies to FXa and thrombin in patients with SLE differentially regulate C3 and C5 cleavage
por: McDonnell, Thomas, et al.
Publicado: (2022)

Optimization of Heparin Monitoring with Anti-FXa Assays and the Impact of Dextran Sulfate for Measuring All Drug Activity
por: Amiral, Jean, et al.
Publicado: (2021)

Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy
por: Demchuk, Andrew M., et al.
Publicado: (2021)

The challenge of pharmacological thromboprophylaxis in ICU patients: anti-FXa activity does not constitute the simple solution. Author's reply
por: Hofmaenner, Daniel A., et al.
Publicado: (2022)

Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations
por: Margetić, Sandra, et al.
Publicado: (2019)

Antiprothrombin antibodies induce platelet activation: A possible explanation for anti‐FXa therapy failure in patients with antiphospholipid syndrome?
por: Chayoua, Walid, et al.
Publicado: (2021)

Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial
por: Bhagirath, Vinai C., et al.
Publicado: (2017)

Rivaroxaban Suppresses Atherosclerosis by Inhibiting FXa-Induced Macrophage M1 Polarization-Mediated Phenotypic Conversion of Vascular Smooth Muscle Cells
por: Ma, Yanpeng, et al.
Publicado: (2021)

Efficient Indium-Mediated Dehalogenation of Aromatics in Ionic Liquid Media
por: Cañete, Álvaro F., et al.
Publicado: (2012)

FXa cleaves the SARS-CoV-2 spike protein and blocks cell entry to protect against infection with inferior effects in B.1.1.7 variant
por: Dong, Wenjuan, et al.
Publicado: (2021)

Identification of Small Molecule Inhibitors of PTPσ through an Integrative Virtual and Biochemical Approach
por: Martin, Katie R., et al.
Publicado: (2012)

Ligand and Structure-Based Approaches for the Identification of Peptide Deformylase Inhibitors as Antibacterial Drugs
por: Gao, Jian, et al.
Publicado: (2016)

Identification of new GLUT2-selective inhibitors through in silico ligand screening and validation in eukaryotic expression systems
por: Schmidl, Sina, et al.
Publicado: (2021)

Targeting RNA:protein interactions with an integrative approach leads to the identification of potent YBX1 inhibitors
por: El Hage, Krystel, et al.
Publicado: (2023)

Novel N-Arylsulfonylindoles Targeted as Ligands of the 5-HT(6) Receptor. Insights on the Influence of C-5 Substitution on Ligand Affinity
por: Arrieta-Rodríguez, Loreto, et al.
Publicado: (2021)

Combined ligand and structure-based virtual screening approaches for identification of novel AChE inhibitors
por: ŞAHİN, Kader, et al.
Publicado: (2020)

Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) Prepared by Microwave and Ultrasound-Assisted Synthesis: Promising Green Strategies for the Nanoworld
por: López, Karla L., et al.
Publicado: (2023)

The role of emotions in educational processes: the conceptions of teacher educators
por: Bachler, Rodolfo, et al.
Publicado: (2023)

Bio-click chemistry: a bridge between biocatalysis and click chemistry
por: Rodríguez, Diego F., et al.
Publicado: (2022)

Identification of Selective BRD9 Inhibitor via Integrated Computational Approach
por: Ali, Maria Mushtaq, et al.
Publicado: (2022)

Integrative biological simulation praxis: Considerations from physics, philosophy, and data/model curation practices
por: Sarma, Gopal P., et al.
Publicado: (2017)

Identification of Mtb GlmU Uridyltransferase Domain Inhibitors by Ligand-Based and Structure-Based Drug Design Approaches
por: Singh, Manvi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_risdp2n46ba2vurrt5pm4lgq1o